ResearcherUniversity of California, San FranciscoActive in the last 2 years
Sunhee S. Kim
Matched on ORCID iD 0000-0002-6477-5679; OpenAlex author ID A5048668257. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 54
2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
- Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
- Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stra… Co-author DOI 10.1097/pas.0000000000001152↗
- Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Co-author DOI 10.1002/jso.24375↗
Closest collaborators
The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Andrew H. Ko · 4 shared papers, 2016–2024 · strength 0.38
- Paper Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancre… DOI 10.1245/s10434-024-15579-0↗
- Paper Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy … DOI 10.1097/pas.0000000000001152↗
- Paper Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level … DOI 10.1093/jnci/djz073↗
- Grace Kim · 3 shared papers, 2016–2024 · strength 0.33
- Paper Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancre… DOI 10.1245/s10434-024-15579-0↗
- Paper Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy … DOI 10.1097/pas.0000000000001152↗
- Paper Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemot… DOI 10.1002/jso.24375↗
- Eric K. Nakakura · 3 shared papers, 2016–2024 · strength 0.33
- Paper Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancre… DOI 10.1245/s10434-024-15579-0↗
- Paper Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy … DOI 10.1097/pas.0000000000001152↗
- Paper Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemot… DOI 10.1002/jso.24375↗
- Kimberly Saunders Kirkwood · 3 shared papers, 2016–2024 · strength 0.33
- Paper Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancre… DOI 10.1245/s10434-024-15579-0↗
- Paper Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy … DOI 10.1097/pas.0000000000001152↗
- Paper Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemot… DOI 10.1002/jso.24375↗
- Margaret A. Tempero · 3 shared papers, 2016–2024 · strength 0.33
- Paper Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancre… DOI 10.1245/s10434-024-15579-0↗
- Paper Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy … DOI 10.1097/pas.0000000000001152↗
- Paper Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemot… DOI 10.1002/jso.24375↗
- Mohamed A. Adam · 1 shared paper, 2024 · strength 0.18
- Adnan A. Alseidi · 1 shared paper, 2024 · strength 0.18
- Phoebe N. Miller · 1 shared paper, 2024 · strength 0.18
- Ajay V. Maker · 1 shared paper, 2024 · strength 0.18
- Jane Wang · 1 shared paper, 2024 · strength 0.18
- Zhen J. Wang · 2 shared papers, 2016–2019 · strength 0.15
- Paper Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy … DOI 10.1097/pas.0000000000001152↗
- Paper Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemot… DOI 10.1002/jso.24375↗
- Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.06
- Christoph Tinchon · 1 shared paper, 2019 · strength 0.06
- Stephen John Clarke · 1 shared paper, 2019 · strength 0.06
- Jaswinder Singh Samra · 1 shared paper, 2019 · strength 0.06
- Kyu‐pyo Kim · 1 shared paper, 2019 · strength 0.06
- Martin D. McCarter · 1 shared paper, 2019 · strength 0.06
- Eric A. Mellon · 1 shared paper, 2019 · strength 0.06
- Johanna W. Wilmink · 1 shared paper, 2019 · strength 0.06
- Niek A. Peters · 1 shared paper, 2019 · strength 0.06
- Jessica M. Frakes · 1 shared paper, 2019 · strength 0.06
- Geertjan van Tienhoven · 1 shared paper, 2019 · strength 0.06
- Derek B. Grose · 1 shared paper, 2019 · strength 0.06
- Maria Antonietta Bali · 1 shared paper, 2019 · strength 0.06
- Sing Yu Moorcraft · 1 shared paper, 2019 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.